Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Subjects (VICTOR-E1).

Trial Profile

Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Subjects (VICTOR-E1).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2013

At a glance

  • Drugs Vicriviroc (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VICTOR-E1
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 11 Jan 2010 48-week results published in the Journal of Infectious Diseases.
    • 14 Sep 2009 96-week results were presented at ICAAC 2009.
    • 13 Sep 2009 96-week tolerability data reported at ICAAC 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top